Ezetimibe

Generic Name
Ezetimibe
Brand Names
Ezetrol, Lypqozet, Nexlizet, Roszet, Vytorin, Zetia
Drug Type
Small Molecule
Chemical Formula
C24H21F2NO3
CAS Number
163222-33-1
Unique Ingredient Identifier
EOR26LQQ24
Background

Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating ...

Indication

Ezetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin). It is also indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, and to reduce elevated...

Associated Conditions
Elevated Blood Lipids, Elevated sitosterol and campesterol
Associated Therapies
-
Clinical Trials
Related News

Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes

First Posted Date
2017-07-02
Last Posted Date
2019-01-10
Lead Sponsor
Yonsei University
Target Recruit Count
150
Registration Number
NCT03204799
Locations
🇰🇷

Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center, Seoul, Korea, Republic of

Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D

First Posted Date
2017-04-07
Last Posted Date
2017-04-07
Lead Sponsor
Aga Khan University
Target Recruit Count
20
Registration Number
NCT03105310

Ezetimibe for Patients With Chronic Hepatitis D

Phase 2
Conditions
Chronic Hepatitis D
Interventions
Drug: Ezetimibe
First Posted Date
2017-04-04
Last Posted Date
2017-04-04
Lead Sponsor
Ziauddin Hospital
Target Recruit Count
20
Registration Number
NCT03099278
Locations
🇵🇰

Ziauddin University Hospital, Karachi, Sindh, Pakistan

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

First Posted Date
2016-12-22
Last Posted Date
2020-05-11
Lead Sponsor
Esperion Therapeutics, Inc.
Target Recruit Count
269
Registration Number
NCT03001076

Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia

First Posted Date
2016-12-07
Last Posted Date
2019-09-09
Lead Sponsor
Sanofi
Target Recruit Count
206
Registration Number
NCT02984982
Locations
🇯🇵

Investigational Site Number 392008, Gifu-shi, Japan

🇯🇵

Investigational Site Number 392022, Chiyoda-ku, Japan

🇯🇵

Investigational Site Number 392039, Hiroshima-shi, Japan

and more 36 locations

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

First Posted Date
2016-09-07
Last Posted Date
2019-09-06
Lead Sponsor
Sanofi
Target Recruit Count
42
Registration Number
NCT02890992
Locations
🇨🇿

Investigational Site Number 2030002, Zlin, Czechia

🇺🇸

Investigational Site Number 8400005, Charlotte, North Carolina, United States

🇺🇸

Investigational Site Number 8400001, Cincinnati, Ohio, United States

and more 13 locations

Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2)

Phase 4
Conditions
Hepatitis C
Interventions
Drug: Ezetimibe
First Posted Date
2016-05-11
Last Posted Date
2016-05-11
Lead Sponsor
Pontificia Universidad Catolica de Chile
Target Recruit Count
12
Registration Number
NCT02768545
Locations
🇨🇱

Departamento de Gastroenterología, Pontificia Universidad Católica de Chile, Santiago, RM, Chile

A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)

Phase 3
Completed
Conditions
Hypercholesterolemia
Interventions
Drug: Rosuvastatin
Drug: Ezetimibe
First Posted Date
2016-04-25
Last Posted Date
2018-06-13
Lead Sponsor
IlDong Pharmaceutical Co Ltd
Target Recruit Count
396
Registration Number
NCT02749994
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)

First Posted Date
2016-04-22
Last Posted Date
2024-05-16
Lead Sponsor
Organon and Co
Target Recruit Count
135
Registration Number
NCT02748057

A Study to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered Alone

First Posted Date
2016-04-06
Last Posted Date
2016-04-06
Lead Sponsor
Alvogen Korea
Target Recruit Count
66
Registration Number
NCT02730689
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy